Evidence map›Paper›PMID 38933967›Full record

ArticleHeliyon2024

Ginsenoside Rd reduces cell proliferation of non-small cell lung cancer cells by p53-mitochondrial apoptotic pathway.

Xilin Wan, Xin Jin, Xinmin Wu, Dan Dong, Hongmei Yang, Renbo Tan, Ying Sun, Xinze Liu, Kaijing Sun, Wei Wu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Ginsenoside Rh4 Triggers Ferroptosis in Lung Cancer: TargetingInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xilin WanJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 130117, China.
Xin JinKey Laboratory of Molecular Epigenetics of the Ministry of Education (MOE), Northeast Normal University, Changchun, 130024, China.
Xinmin WuDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, 130021, China.
Dan DongGynaecology and Obstetrics Center, First Hospital of Jilin University, Changchun, 130021, China.
Hongmei YangThe Public Experimental Center, Changchun University of Chinese Medicine, Changchun, 130117, China.
Renbo TanNortheast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China.
Ying SunClinical Laboratory, The Second Affiliated Hospital of Dalian Medical University, 116023, Dalian, China.
Xinze LiuJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 130117, China.
Kaijing SunJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 130117, China.
Wei WuJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 130117, China.
Changbao ChenJilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, 130117, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ginsenoside Rd is a tetracyclic triterpenoid derivative, widely existing in

Indexed as

95-DAnti-proliferationGinsenoside RdMitochondrial apoptoticNCI–H460Non-small cell lung cancer

Identifiers

PMID38933967
PMCPMC11201117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.